Premium
Long‐term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis
Author(s) -
LloydLavery A.
Publication year - 2018
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.17016
Subject(s) - tofacitinib , janus kinase inhibitor , psoriasis , janus kinase , medicine , dermatology , term (time) , plaque psoriasis , ruxolitinib , pharmacology , myelofibrosis , rheumatoid arthritis , physics , quantum mechanics , cytokine , bone marrow
Linked Article: Valenzuela et al. Br J Dermatol 2018; 179 :853–862.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom